Weight loss pills can make the treatment of obesity a revolution

In a step that can have a fundamental shift in obesity, pharmaceutical businesses develop new GLP-1 pills, which are currently used in weekly injection medicine such as Wigofi and Ozmebek to lose weight, according to a CNN report. The GLP-1 is a natural hormone that is secreted after eating the small intestine, and plays an important role in regulating blood sugar and levels of appetite through multiple effects. And when the blood sugar level increases after eating, the GLP-1 pancreas helps the insulin secretion that lowers sugar levels, which helps to feel a longer period after eating, and reduces the desire to eat more food. These pills are still at the stages of final clinical trials, and it can facilitate patients to treat daily without requiring injection, which provides greater ease, and expands the extent of using this effective medicine in anti -obviousity. The report has dr. Judy Doshai, an assistant professor at Harvard Medical College, quoted that this new medicine could open new horizons in weight management, but needed more research to ensure their safety and the efficacy of their long -term use. The medical scene is currently seeing a revolution in the treatment of weight gain; Thanks to a new category of medicine that depends on the hormone GLP-1, as this medication came into the form of injection that is taken once a week, but the pills containing the same active substance can be very close to reaching the markets. This medicine intended for weight loss and diabetes has become very popular thanks to their remarkable effects on weight loss, but the injection problem remains a hindrance to many patients who fear needles. But this obstacle may soon disappear with the prevalence of pills, and many businesses are currently working on the development of pills that depend on the same principle; At least 12 similar medicines are currently subject to clinical trials, and the most advanced in the third phase of tests. Equal results with Wigofi and Ozmebek. According to the report, the researchers say these pills have the ability to significantly change the scene of weight control, as early clinical tests have shown pills containing ‘simaglotide’, which is the same active substance found in Wigofi and Ozmebek. The results of clinical trials indicate that patients who consumed these pills daily lost almost 15% of their weight within 68 weeks, a rate of loss similar to that were recorded with the injection. The use of pills has some challenges as it must be taken on an empty stomach, and it is not allowed half an hour to eat or drink, and the dose designated for weight loss in the grains is much higher than diabetes, which increases the possibility of side effects such as nausea, vomitation and abdominal pain. Doctors will also face the possibility of abuse of this medication, especially if it comes in the form of daily pills, which can facilitate inappropriate eating or share it with others, which is what doctors who indicate that more research is needed to understand the long -term consequences of these pills. Research indicates that the GLP-1 medicine is not only useful for weight loss, but can also contribute to the protection of the heart and improving public health, and these benefits can make hormonal medicines an important component in managing chronic diseases such as diabetes and obesity.